Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics PLC has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd, potentially earning up to $25 million in milestone payments and a royalty on sales. This strategic move is part of a broader group restructuring, which includes the sale of its subsidiary Lyramid Pty Ltd to Pleiades, contingent on successful fundraising. The restructuring aims to benefit existing shareholders and allow Roquefort to focus on a transformative acquisition with A2A Pharmaceuticals and Coiled Therapeutics, enhancing its position in the biotech industry.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market of the London Stock Exchange. The company is focused on acquiring exclusive license rights to AO-252, a novel drug targeting the TACC3 protein for cancer treatment. Roquefort Therapeutics is also involved in the development of the MK Cell program and the STAT-6 program.
Average Trading Volume: 2,022,137
Technical Sentiment Signal: Sell
Current Market Cap: £2.91M
Learn more about ROQ stock on TipRanks’ Stock Analysis page.